PURPOSE: To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. METHODS: A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. RESULTS: With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8-10. The retrospective approach is a limitation of our study. CONCLUSIONS: Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual's risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.
PURPOSE: To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. METHODS: A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. RESULTS: With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8-10. The retrospective approach is a limitation of our study. CONCLUSIONS: Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual's risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.
Authors: D G Bostwick; D J Grignon; M E Hammond; M B Amin; M Cohen; D Crawford; M Gospadarowicz; R S Kaplan; D S Miller; R Montironi; T F Pajak; A Pollack; J R Srigley; J W Yarbro Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Alberto Briganti; Thomas Wiegel; Steven Joniau; Cesare Cozzarini; Marco Bianchi; Maxine Sun; Bertrand Tombal; Karin Haustermans; Tom Budiharto; Wolfgang Hinkelbein; Nadia Di Muzio; Pierre I Karakiewicz; Francesco Montorsi; Hein Van Poppel Journal: Eur Urol Date: 2012-05-16 Impact factor: 20.096
Authors: Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-23 Impact factor: 7.038
Authors: Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Andrew J Stephenson; Scott E Eggener; Adrian V Hernandez; Eric A Klein; Michael W Kattan; David P Wood; Danny M Rabah; James A Eastham; Peter T Scardino Journal: Eur Urol Date: 2013-08-27 Impact factor: 20.096
Authors: Johnny Ray Bernard; Steven J Buskirk; Michael G Heckman; Nancy N Diehl; Stephen J Ko; Orlan K Macdonald; Steven E Schild; Thomas M Pisansky Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-21 Impact factor: 7.038
Authors: David Pfister; Michel Bolla; Alberto Briganti; Peter Carroll; Cesare Cozzarini; Steven Joniau; Hein van Poppel; Mack Roach; Andrew Stephenson; Thomas Wiegel; Michael J Zelefsky Journal: Eur Urol Date: 2013-08-15 Impact factor: 20.096
Authors: Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gregor Weirich; Michael Autenrieth; Tobias Maurer; Mark Thalgott; Thomas Horn; Matthias Heck; Kathleen Herkommer; Jürgen E Gschwend; Hubert Kübler Journal: World J Urol Date: 2015-06-23 Impact factor: 4.226
Authors: M Schostak; F König; M Bögemann; P Goebell; P Hammerer; S Machtens; C Schwentner; C Thomas; G von Amsberg; F-C von Rundstedt; A Heidenreich Journal: Urologe A Date: 2018-07 Impact factor: 0.639
Authors: Georgios Hatzichristodoulou; Stefan Wagenpfeil; Gudrun Wagenpfeil; Tobias Maurer; Thomas Horn; Kathleen Herkommer; Marie Hegemann; Jürgen E Gschwend; Hubert Kübler Journal: World J Urol Date: 2015-09-29 Impact factor: 4.226
Authors: Che Hseuh Yang; Yi Sheng Lin; Yen Chuan Ou; Wei Chun Weng; Li Hua Huang; Chin Heng Lu; Chao Yu Hsu; Min Che Tung Journal: World J Clin Cases Date: 2021-02-16 Impact factor: 1.337